NP
RVNC

NorthRock Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

NorthRock Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,162
Closed -$129K – 880
2024
Q2 		$129K Buy
50,162
+19,454
+63% +$66.4K ﹤0.01% 602
2024
Q1 		$151K Buy
+30,708
New +$182K 0.01% 605

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

NorthRock Partners's RVNC Position: Q3 2024 in Review

NorthRock Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 50,162 shares — an estimated $129K sold.

NorthRock Partners first reported a position in RVNC in Q1 2024 and held it in 2 quarters. The position peaked at $151K in Q1 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • NorthRock Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • NorthRock Partners sold 50,162 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $129K.
  • NorthRock Partners first reported a position in Revance Therapeutics, Inc. in Q1 2024 and held it in 2 quarters.
  • NorthRock Partners's Revance Therapeutics, Inc. position peaked at $151K in Q1 2024.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on NorthRock Partners's 13F filing for Q3 2024, filed 30 Oct 2024.